Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma

Clinical Advances in Hematology and Oncology

Volumn 6, Issue 6, 2008, Pages 437-445

  Leonard, John P ^a,g   Gregory, Stephanie A ^b   Maloney, David G ^c   Vose, Julie M ^d   Younes, Anas ^e   Zelenetz, Andrew D ^f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Bendamustine; Bortezomib; Lenalidomide; Non Hodgkin lymphoma; Radioimmunotherapy

Indexed keywords

ALEMTUZUMAB; AME 133; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BORTEZOMIB; CD20 ANTIBODY; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GA 101; HUMAX CD 20; IBRITUMOMAB TIUXETAN; IMMU 106; IMMUNO 106; IMMUNOSUPPRESSIVE AGENT; IODINE 131; LENALIDOMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD2; MONOCLONAL ANTIBODY CD80; OFATUMUMAB; PLACEBO; PREDNISONE; PRO 70769; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TREANDA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; YTTRIUM 90;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EARLY INTERVENTION; FATIGUE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; GRANULOCYTOPENIA; HUMAN; INFECTION; LEUKOPENIA; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PNEUMONIA; RADIOIMMUNOTHERAPY; RECURRENT CANCER; REDUCED INTENSITY CONDITIONING; REVIEW; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, NON-HODGKIN; NEOPLASM RECURRENCE, LOCAL; PROTEASE INHIBITORS; RADIOIMMUNOTHERAPY;

EID: 52949089961     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. McLaughlin P. Progress and promise in the treatment of indolent lymphomas. Oncologist. 2002;7:217-225.
2. Ganti AK, Bociek RG, Bierman PJ, et al. Follicular lymphoma: expanding therapeutic options. Oncology (Williston Park). 2005;19:213-228. Discussion 228, 233-236, 239.
3. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909-3918.
4. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 throughs 1995. J Natl Cancer Inst. 2000;92:1240-1251.
5. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265-276.
6. Aurora V, Winter JN. Follicular lymphoma: today's treatments and tomorrow's targets. Expert Opin Pharmacother. 2006;7:1273-1290.
7. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516-522.
8. Lichtman M, Beutler E, Kipps T. Williams Hematology. New York, NY: McGraw-Hill; 2006.
9. Cheung MC, Haynes AE, Meyer RM, Stevens A, Imrie KR. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. Cancer Treat Rev. 2007;33:161-176.
10. National Comprehensive Cancer Network website. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphoma. V.2.2008. http://nccn.org/professionals/physician_gls/PDF/nhl.pdf. Accessed April 7, 2008.
11. Ezdinli EZ, Anderson JR, Melvin F, et al. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol. 1985;3:769-775.
12. Lister TA, Cullen MH, Beard ME, et al. Comparison of combined anti single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. Br Med J. 1978;1:533-537.
13. Kimby E, Bjorkholm M, Gahrton G, et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol. 1994; 5:67-71.
14. McLaughlin P, Cabanillas F, Hagemeister FB, et al. CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol. 1993;4:205-211.
15. Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent folliculax lymphomas: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2003;21:5-15.
16. Kennedy BJ, Bloomfield CD, Kiang DT, et al. Combination versus successive single agent chemotherapy in lymphocytic lymphoma. Cancer. 1978;41:23-28.
17. Winter JN, Gascoyne RD, Van Besien K. Low-grade lymphoma. Hematology (Am Soc Hematol Educ Program). 2004:203-220.
18. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423.
19. Cruczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Ontol. 2004;22:4711-4716.
20. Witzig TE, Flinn JW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkins's lymphoma. J Clin Oncol. 2002;20:3262-3269.
21. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565-7573.
22. Dang NH, Fayad L, McLaughlin P, et al. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2007;138:502-505.
23. El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18:1363-1368.
24. Marcus R. Use of rituximab in patients with follicular lymphoma. Clin Oncol (R Coll Radiol). 2007;19:38-49.
25. Leonard JP. Targeting CD20 in follicular NHL: novel anti-CD20 therapies. antibody engineering, and the use of radioimmunoconjugates. Hematology. 2005;2005:335-339.
26. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793-1800.
27. Hagenbeek A, Plesner T, Walewski. A novel fully humane anti-CD20 monoclonal antibody, first clinical trial results from an ongoing phase I/II trial in patients with follicular non-Hodgkin's lymphorma. Ann Oncol. 2005;16: Abstract 114.
28. Vugmeyster Y, Beyer J, Howell K, et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother. 2005; 28:212-219.
29. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combinations with the humanized anti-CD22 antibody epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res. 2004;10:2868-2878.
30. Weiner GJ, Bowles JA, Link BK, et al. Anti-CD20 monoclonal antibody (mAb) with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab (R). Blood. 2005;106: Abstract 348.
31. Umana P, Moessner E, Bruenker P, et al. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Blood. 2006;108. Abstract 229.
32. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs. 2007;67:333-350.
33. Maloney DG. Follicular NHL: frosts antibodies and vaccines to graft-versus-lymphoma effects. Hematology. 2007;2007:226-232.
34. Cell Therapeutics Inc. http://www.zevalin.com/pdf/ Zevalin_PI_website.pdf. Accessed April 17, 2008.
35. GlaxoSmithKline. Bexxar Complete Prescribing Information. http://us.gsk.com/products/assets/us_bexxar.pdf. Accessed April 17, 2008.
36. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
37. DeMonaco NA, Wu M, Osborn J, et al. Phase II trial of abbreviated CHOP-rituximab followed by 90Y ibritumomab tiuxetan (Zevalin) and rituximab in patients with previously-untreated follicular non-Hodgkin lymphoma (NHL). Blood. 2005;106: Abstract 2449.
38. Hagenbeek A, Bischof-Delaloye A, Radford JA, et al. 90Y-Ibritumomab riuxetan (Zevalin(R)) consolidation of first remission in advanced stage follicular non-Hodgkin's lymphoma: first results of the international randomized phase 3 First-Line Indolent Trial (FIT) in 414 Patients. Blood. 2007;110: Abstract 643.
39. Jankowitz RC, Foon KA, DeMonaco NA, et al. Phase II study of short course CHOP-rituximab (R) followed by ibritumomab tiuxetan (IT) as first-line treatment for follicular lymphoma (FL). J Clin Oncol. 2007;25: Abstract 8005.
40. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Ontol. 2005;23:712-719.
41. Ogura M, Morishima Y, Watanabe T, et al. 90Y Ibritumomab tiuxetan (Y2B8, Zevalin (R)) radioimmunotherapy (RIT) is highly effective for relapsed or refractory indolent B-cell non-Hodgkin's lymphoma (B-NHL) pretreated with rituximab-containing chemotherapy (R-Chemo): Japanese Multicenter Phase II Study. Blood. 2006;108: Abstract 2767.
42. Kaminski MS, Tuck M, Ester J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
43. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005; 23:5696-5704.
44. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143-4149.
45. Connors JM. Radioimmunotherapy - hot new treatment for lymphoma. N Engl J Med. 2005;352:496-498.
46. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323.
47. Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2004;22:1469-1479.
48. Leonard JP, Furman RR, Coleman M. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Int J Cancer. 2006;119:971-979.
49. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002;99:14374-14379.
50. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101: 1530-1534.
51. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lyomphoma. J Clin Oncol. 2005;23:676-684.
52. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:667-675.
53. Strauss SJ, Maharaj L, Hoare S, et al, Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol. 2006;24:2105-2112.
54. O'Connor O, Wright J, Moskowitz C, et al. Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: results of a multicenter phase II experience. Ann Oncol. 2005;16(suppl 5):v66. Abstract 099.
55. De Vos S, Dakhil S, McLaughlin P. Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: final results. Blood. 2006;108:208a. Abstract 694.
56. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and bas a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383-3389.
57. Weidmann E, Kim SZ, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13:1285-1289.
58. Friedberg JW, Cohen P, Cheson BD. Bendamustine HCI (TREANDA) treatment results in high rates of objective response in patients with rituximab-refractory and alkylator-refractory indolent B-cell non-Hodgkin's lymphoma (NHL): results from a phase II multicenter single-agent study (SDX-105-01). Blood. 2005;106: Abstract 229.
59. Van det Jagt R, Cohen P, Cheson B, al e. Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin's lymphoma. Blood. 2006;108:766a. Abstract 2710.
60. Weide R, Hess G, Koppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma. 2007;48:1299-1306.
61. Rummel M, Atta J, Welslau M. Bendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas: long-term follow-tip of a phase II study. J Clin Oncol. 2007;25:457s. Abstract 8066.
62. Witzig T, Vose J, Pietronigro D. Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2007. 2007;25:457, Abstract 8066.
63. Wiernik PH, Lossos I, Tuscano J. Preliminary results from a phase II study of lenalidomide monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma. Blood. 2006:108:160a. Abstract 531.
64. Reddy N, Cruz R, Hernandez-Ilizaliturri F. Lenalidomide (Revlimid) enhances monoclonal antibody-associated anti-tumor activity against rituximab-sensitive and rituximab-resistant B-cell lymphoma cell lines. Blood. 2006;108:714a. Abstract 2522.
65. Hosing C, Saliba RM, McLaughlin P, et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol. 2003;14:737-744.
66. Rohatiner AZ, Johnson PW, Price CG, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol. 1994;12:1177-1184.
67. Schouren IC, Raemaekers JJ, Kluin-Nelemans HC, et al. High-dose therapy followed by bone marrow transplantation for relapsed follicular non-Hodgkin's lymphoma. Dutch HOVON Group. Ann Hematol. 1996;73:273-277.
68. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
69. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-3400.
70. Gribben JG. How I treat indolent lymphoma. Blood. 2007;109:4617-4626.
71. Wiseman G, Gordon L, Multani P. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002;99:4336-4342.
72. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+v B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004;103:4429-4431.